NasdaqGS:MDGLBiotechs
A Fresh Look at Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Launch and Pipeline Progress
Madrigal Pharmaceuticals (MDGL) is riding a wave of momentum following the strong debut of Rezdiffra, its novel therapy for metabolic dysfunction-associated steatohepatitis, or MASH. Early numbers suggest significant potential as U.S. adoption picks up.
See our latest analysis for Madrigal Pharmaceuticals.
On the heels of Rezdiffra’s strong launch and a steady drumbeat of positive developments, including the recent in-licensing of a GLP-1 drug, Madrigal Pharmaceuticals’ share price has...